Biotechpharma UAB, a biopharmaceutical CDMO, has invested more than €50 million to further expand its fermentation capacity to 5,000 L, along with a new process development lab.
 
Dr. Vladas Bumelis, chairman of the board, said, “The expansion comes amid growing global demand for flexible and responsive outsourcing partners that are able to support the full product lifecycle, from upstream and downstream process development and optimization to GMP manufacturing of drug substance and formulated drug product.”
 
“We are thrilled to announce this latest expansion of our infrastructure, as it will allow us to better support our customers’ biological development programs with quality, speed and flexibility of service,” said Giedrius Žunda, chief executive officer of Biotechpharma.

The new plant located at the company’s site in Vilnius, Lithuania, will contain a new line of bioreactors for microbial fermentation at 5,000 L scale and the necessary equipment for downstream processing operations. The flexible facility design will also allow for increased mammalian cell culture production capacities in addition to the existing two lines of 1000-L and 2000-L scale for mammalian cell production, both equipped with single-use bioreactors. Completion of the plant, which should be operational in 4Q20, will result in an increase in volume capacity by nearly double.